POLPHARMA-BIOLOGICS
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has received notification by the U.S. Food and Drug Administration (FDA) that the biologics license application (BLA) for its proposed biosimilar (formally also known as BQ201, FYB201, CHS-201) to Lucentis® , a blockbuster ophthalmological drug containing ranibizumab as active drug substance, has been accepted for review.
The FDA has assigned a target action date for the application for August 2022.
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "wet" type of age-related macular degeneration, a common form of age-related vision loss. Worldwide, at least 25 to 30 million people are affected by age-related macular degeneration. The launch of a biosimilar Ranibizumab can increase market competition, reduce cost and expand patient access with proven analytical and clinical similarity to the original product.
This file acceptance represents the most recent milestone for Bioeq`s ranibizumab biosimilar program and compliments marketing authorization applications submitted to EMA in June and UK MHRA in July this year.
Subject to the FDA`s approval, BQ201 will be exclusively commercialized by Coherus BioSciences, Inc. in the United States.
Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented on the achievements of the joint venture:
“This file acceptance is validation of the huge effort put in by the team at Bioeq and its partners to bring treatment choice and improved patient access to the US market. It creates real promise for those who suffer from debilitating vision loss, including age-related macular degeneration.”
- Lucentis® is a registered trademark of Genentech Inc.
Information for editors
About Ranibizumab biosimilar
Bioeq`s proposed ranibizumab biosimilar BQ201, previously designated as FYB201 (and also known as CHS-201), has been originally licensed from Formycon AG (FRA: FYB/ WKN A1EWVY), a leading German biosimilars company, and subsequently developed by Bioeq AG, a joint venture between Polpharma Biologics and Santo Holding AG (Strüngmann Group). Phase III clinical trials for FYB201 have clinically demonstrated that the efficacy of FYB201 in patients with nAMD is comparable to that of Lucentis® .
About biosimilars
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.
About Polpharma Biologics Group
The Polpharma Biologics Group creates quality biosimilars with a passion to improve lives of patients. The group has built an extensive and growing pipeline of biosimilars to treat a number of medical conditions across major therapeutic areas. Several of these biosimilar assets have already been commercially partnered with the world’s largest biopharmaceutical companies.
The group operates a network of state-of-the-art development and manufacturing facilities across Europe, actively investing in technology, people and know-how, employing over 800 specialists from around the globe.
Learn more at www.polpharmabiologics.com
About Bioeq
Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005408/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
When Regulation and AI Converge: SymphonyAI Joins the FCA Supercharged Sandbox to Pioneer Responsible Fintech Innovation19.11.2025 08:00:00 CET | Press release
SymphonyAI joins the FCA’s new Supercharged Sandbox to advance explainable, responsible AI innovation for UK financial services SymphonyAI, a global leader in Vertical AI product platforms, has been selected to participate in the UK’s Financial Conduct Authority’s (FCA) Supercharged AI Sandbox, a new initiative enabling firms to safely develop and test advanced AI technologies using NVIDIA (NVDA) accelerated computing within a supervised regulatory environment. SymphonyAI Financial Services was selected following a competitive application process that evaluated proposed use cases for innovation potential, technical feasibility, and regulatory impact. Running from September 2025 to January 2026, the Sandbox offers a secure, structured environment for experimentation on next-generation AI use cases. SymphonyAI is developing an AI agent concept powered by small language models and reinforcement learning, designed to advance the intelligence and autonomy of financial services agents. If su
Regnology Launches RRH Ascend, Leveraging Straight-Through Reporting to Modernize Financial Regulation19.11.2025 08:00:00 CET | Press release
Regnology, a leading software provider with a focus on regulatory reporting and supervisory technology solutions, today announced the launch of RRH Ascend, the next generation of its Regnology Reporting Hub (RRH) solution for banking and transaction reporting. The unveiling will take place at the 32nd annual RegTech Convention, the largest global conference on financial regulation, which brings together more than 2,000 participants across nine cities in a hybrid format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118412298/en/ RRH Ascend marks a major step towardStraight-Through Reporting (STR)—a new standard designed to eliminate friction in regulatory processes through end-to-end automation, seamless data integration, and intelligent oversight. Modeled on the principles of Straight-Through Processing (STP) in capital markets, STR enables continuous, data-driven exchanges between institutions and regulators, reducing
LTIMindtree Strengthens Relationship with Microsoft to Accelerate Microsoft Azure Adoption and Drive AI-Powered Transformation19.11.2025 07:00:00 CET | Press release
Collaboration to enable robust enterprise growth through advanced security and trusted governance offerings LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced expansion of its global collaboration with Microsoft to accelerate Microsoft Azure adoption and drive AI-powered business transformation for enterprises. As a part of this collaboration, LTIMindtree will enable faster cloud adoption and unlock enhanced business value for joint customers through advanced AI solutions. As a Global System Integrator (GSI) partner for Microsoft, LTIMindtree is deepening its commitment to enable global enterprises to maximize their cloud investments, Azure commits and achieve faster time-to-value. This collaboration underscores LTIMindtree’s ambition to deliver significant growth in Azure-related engagements, leveraging the strength of its 360° relationship with Microsoft across all the solution areas. It combines LTIMindtree’s industry ex
EsriIntroduces Latest ArcGIS Integrations for Microsoft Fabric18.11.2025 23:05:00 CET | Press release
Users Can Now Access a Powerful Combination of Spatial Analytics and Intelligent Mapping Esri, the global leader in location intelligence, today announced General Availability of ArcGIS GeoAnalytics for Microsoft Fabric. Also now in public preview is ArcGIS Maps for Microsoft Fabric, a mapping tool enabling users to easily add context with business, lifestyle, demographic, and environmental data to enrich enterprise data in Microsoft OneLake. “This integration makes some of Esri’s core capabilities accessible for data professionals directly from their Microsoft Fabric environment,” said Jack Dangermond, Esri president. “We are pleased to advance our long-standing strategic collaboration with Microsoft to help our shared customers unlock spatial insights and reveal unexplored patterns.” There has been growing market demand among data scientists, data engineers, business analysts, and their executive stakeholders for spatial analytics and mapping. Esri’s GeoAnalytics for Fabric will allo
Andersen Consulting indgår samarbejdsaftale med Business Meets Culture18.11.2025 22:18:00 CET | Pressemeddelelse
Andersen Consulting udvider sin globale rækkevidde gennem en samarbejdsaftale med Business Meets Culture (BMC), der er en global strategikonsulentvirksomhed med lokationer i Latinamerika, Europa og USA. Med afsæt i kulturel intelligens og indsigt i menneskelig adfærd specialiserer BMC sig i strategi, brandstrategi, kommerciel planlægning, innovation og altid transformation. Med deres egne metoder og tværfaglige teams hjælper BMC virksomheder med at knytte strategi tættere til mennesker ved at omsætte udvikling, adfærd og forretningsmæssige udfordringer til relevante muligheder for vækst. Virksomheden samarbejder med førende aktører på tværs af brancher som forbrugsvarer, finansielle tjenester, telekommunikation og teknologi. "Samarbejdet med Andersen Consulting giver os mulighed for at styrke rækkevidden og effekten af vores kulturelt forankrede strategiske arbejde," siger Fernando Parodi, som er CEO for BMC. "Sammen står vi endnu stærkere og kan tilbyde organisationer skarpere perspek
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom